Evaluation of Nano-crystalline Hydroxyapatite Silica Gel in Management of Periodontal Intrabony Defects

Clinical and Radiographic Evaluation of Nano-crystalline Hydroxyapatite Silica Gel in the Treatment of Human Periodontal Intrabony Defects

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02507596

Enrollment

Registered

2015-07-24

Start date

2015-04-30

Completion date

2019-12-31

Last updated

2022-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Periodontitis

Brief summary

A clinical and radiographic evaluation of Nano-crystalline hydroxyapatite silica gel in comparison with open flap debridement for management of periodontal intrabony defects.

Detailed description

Thirty patients suffering from advanced chronic periodontitis were included in this randomized controlled clinical trial. Each subject contributed matched two- or three-walled intrabony defects. Patients were equally assigned into the experimental group; Nano-crystalline hydroxyapatite silica gel or the negative control group;open flap debridement. Clinical and radiographic parameters were recorded at baseline and at 3 and 6 months postoperatively.

Interventions

BIOLOGICALNano-crystalline hydroxyapatite silica gel

it is a type of synthetic bone graft.

PROCEDUREopen flap debridement

a periodontal surgical procedure for the purpose of debridement.

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

35 Years to 50 Years

Healthy volunteers

Yes

Inclusion criteria

* Severe chronic periodontitis patients. * having at least one site with pocket depth ≥ 6 mm and clinical attachment level ≥ 5 mm, with radiographic evidence of bone loss as detected in periapical radiographs.

Exclusion criteria

* Pregnant women * Subjects had \<22 permanent teeth * Having any given systemic disease * Taking any type of medication and/or antibiotic therapy during the 3 months before the study * Received periodontal treatment within the past 12 months Current or former smokers

Design outcomes

Primary

Measure	Time frame	Description
Clinical attachment level	change from Baseline at 6 months	Change from baseline in clinical attachment level in mm in chronic periodontitis patients at 6 month

Secondary

Measure	Time frame	Description
pocket depth	Baseline and 6 months	Estimation of pocket depth in mm in chronic periodontitis patients at baseline and 6 months
bone defect area	Baseline and 6 months	Estimation of bone fill defect area in mm square in chronic periodontitis patients at baseline and 6 month

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026